Evidence map›Paper›PMID 36983474›Full record

ArticleJournal of fungi (Basel, Switzerland)2023

Roya Vahedi-Shahandashti, Lisa Hahn, Jos Houbraken, Cornelia Lass-Flörl

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of fungi (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Antifungal susceptibility ofFrontiers in public health · 2026
    Article
  3. Antimicrobial agents and chemotherapy · 2025
    Article
  4. DecipheringMicrobiology spectrum · 2025
    Article
  5. Journal of fungi (Basel, Switzerland) · 2023
    Article
  6. Article
  7. Novel Antifungals andJournal of fungi (Basel, Switzerland) · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Roya Vahedi-ShahandashtiInstitute of Hygiene and Medical Microbiology, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Lisa HahnInstitute of Hygiene and Medical Microbiology, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Jos HoubrakenWesterdijk Fungal Biodiversity Institute, 3584 CT Utrecht, The Netherlands.
Cornelia Lass-FlörlInstitute of Hygiene and Medical Microbiology, Medical University of Innsbruck, 6020 Innsbruck, Austria.ORCID 0000-0002-2946-7785
Innsbruck Medical University · ATWesterdijk Fungal Biodiversity Institute · NL

Funding

FWF Austrian Science Fund W1253-B24
6 · The paper itself

Abstract

Providing timely antifungal treatment to patients suffering from life-threatening invasive fungal infections (IFIs) is essential. Due to the changing epidemiology and the emergence of antifungal resistance in

Indexed as

amphotericin Bantifungal resistanceantifungal susceptibility testingAspergillus terreusclinical breakpointsCLSIepidemiological cutoff valuesEUCASTisavuconazole

Identifiers

PMID36983474
PMCPMC10056208
OpenAlexW4322631029

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.